News Releases Keyword Search Year None2019201820172016 Dec-12-2019 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium Dec-11-2019 Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma Dec-09-2019 Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting Dec-03-2019 Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium Nov-21-2019 Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference Nov-14-2019 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting Nov-11-2019 Oncternal Therapeutics to Present at Stifel Healthcare Conference Nov-07-2019 Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update Nov-05-2019 Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting Oct-31-2019 Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »